EGFR and non-small cell lung carcinoma: Likewise, patients with unresectable locally advanced NSCLC whose disease has not progressed after concurrent platinum-based CRT can receive consolidation therapy with durvalumab (a PD-L1 inhibitor) or osimertinib (if carrying EGFR-mutated NSCLC) according to specific regional guidance [17, 21–24].